[{"id":"17d5dfd7-684d-4f90-850e-e14953c32f5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04091867","created_at":"2021-01-18T20:01:30.016Z","updated_at":"2025-02-25T12:37:25.866Z","phase":"Phase 1","brief_title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","source_id_and_acronym":"NCT04091867","lead_sponsor":"University of Colorado, Denver","biomarkers":" EPHB4","pipe":" | ","alterations":" EGFR expression • CDKN2A negative","tags":["EPHB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/06/2020","start_date":" 01/06/2020","primary_txt":" Primary completion: 05/14/2021","primary_completion_date":" 05/14/2021","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2025-02-24"},{"id":"0f9bc919-4e69-4675-bc62-35e94a94fa58","acronym":"INT22-09-01","url":"https://clinicaltrials.gov/study/NCT05521698","created_at":"2022-08-30T20:56:03.144Z","updated_at":"2025-02-25T13:41:12.118Z","phase":"Phase 1","brief_title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT05521698 - INT22-09-01","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/23/2025","start_date":" 04/23/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-21"},{"id":"a00222c5-3654-4b1c-8e1f-3f6063d2350d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03083678","created_at":"2021-01-18T15:11:26.156Z","updated_at":"2025-02-25T15:10:32.768Z","phase":"Phase 2","brief_title":"Afatinib in Locally Advanced and Metastatic Chordoma","source_id_and_acronym":"NCT03083678","lead_sponsor":"Leiden University Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-13"},{"id":"5f3b5bbb-9aff-4571-a252-57e8a1171808","acronym":"CHRYSALIS-2","url":"https://clinicaltrials.gov/study/NCT04077463","created_at":"2021-01-18T19:58:05.927Z","updated_at":"2025-02-25T15:34:28.760Z","phase":"Phase 1","brief_title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04077463 - CHRYSALIS-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 701","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 02/03/2025","primary_completion_date":" 02/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2025-02-11"},{"id":"92c099b7-baf6-420f-bbb6-7c2961993e03","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674526","created_at":"2023-01-06T15:58:52.282Z","updated_at":"2025-02-25T16:39:35.039Z","phase":"Phase 1","brief_title":"A Phase 1b Study of WU-NK-101 in Combination With Cetuximab","source_id_and_acronym":"NCT05674526","lead_sponsor":"Wugen, Inc.","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • EGFR expression • RAS mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • EGFR expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • WU-NK-101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-07"},{"id":"41be4368-ac8d-41a5-97f4-07c00abcbd42","acronym":"ADAPT-E","url":"https://clinicaltrials.gov/study/NCT04585477","created_at":"2023-03-02T18:01:37.004Z","updated_at":"2025-02-25T14:59:23.663Z","phase":"Phase 2","brief_title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","source_id_and_acronym":"NCT04585477 - ADAPT-E","lead_sponsor":"Stanford University","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"80d5522f-7e62-4840-9814-99046b8adfc5","acronym":"DEKA-1","url":"https://clinicaltrials.gov/study/NCT05704985","created_at":"2023-01-30T15:59:33.980Z","updated_at":"2025-02-25T17:31:52.518Z","phase":"Phase 1","brief_title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","source_id_and_acronym":"NCT05704985 - DEKA-1","lead_sponsor":"DEKA Biosciences","biomarkers":" EGFR • IL2 • IL10","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-23"},{"id":"117dd7b5-3dd5-44f8-ae41-dd01937e2c0d","acronym":"EGFR","url":"https://clinicaltrials.gov/study/NCT06606301","created_at":"2025-02-26T14:54:38.136Z","updated_at":"2025-02-26T14:54:38.136Z","phase":"","brief_title":"Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT06606301 - EGFR","lead_sponsor":"Combined Military Hospital, Pakistan","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 08/26/2023","start_date":" 08/26/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/28/2023","study_completion_date":" 12/28/2023","last_update_posted":"2024-09-24"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"42d098db-7735-4ec6-beca-081467347e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254384","created_at":"2021-01-18T00:51:46.726Z","updated_at":"2024-07-02T16:35:01.822Z","phase":"Phase 1","brief_title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","source_id_and_acronym":"NCT00254384","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/05/2005","start_date":" 10/05/2005","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-05-23"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"2638658d-5de1-4c1e-afa0-e9fef20584a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01327781","created_at":"2021-01-18T05:24:42.319Z","updated_at":"2024-07-02T16:35:17.724Z","phase":"Phase 1","brief_title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT01327781","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K","pipe":" | ","alterations":" ER positive • HER-2 expression • EGFR expression","tags":["EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 03/25/2011","start_date":" 03/25/2011","primary_txt":" Primary completion: 03/05/2017","primary_completion_date":" 03/05/2017","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-02-26"},{"id":"d9c9428c-3a59-4384-ad4e-5e3646ac2fde","acronym":"TAVO412","url":"https://clinicaltrials.gov/study/NCT05548634","created_at":"2022-09-21T18:56:21.079Z","updated_at":"2024-07-02T16:35:26.126Z","phase":"Phase 1","brief_title":"A Study of TAVO412 in Patients With Cancer","source_id_and_acronym":"NCT05548634 - TAVO412","lead_sponsor":"Tavotek Biotherapeutics","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP412 • TAVO412"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-15"},{"id":"fe9a8c97-4137-4e63-9045-01b237294fe6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04629209","created_at":"2021-01-19T20:36:09.384Z","updated_at":"2024-07-02T16:35:28.119Z","phase":"Phase 2","brief_title":"A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma","source_id_and_acronym":"NCT04629209","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-11-24"},{"id":"4012ef46-eb93-4087-876c-82a648c0d4c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400915","created_at":"2022-06-02T16:58:54.112Z","updated_at":"2024-07-02T16:35:29.638Z","phase":"Phase 1/2","brief_title":"Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients","source_id_and_acronym":"NCT05400915","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • varlitinib (ASLAN001)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 07/23/2019","start_date":" 07/23/2019","primary_txt":" Primary completion: 12/13/2021","primary_completion_date":" 12/13/2021","study_txt":" Completion: 06/13/2022","study_completion_date":" 06/13/2022","last_update_posted":"2023-11-10"},{"id":"4f4758bc-898a-4693-b042-1a465776cfac","acronym":"ADJUVANT BR.31","url":"https://clinicaltrials.gov/study/NCT02273375","created_at":"2021-01-18T10:41:44.787Z","updated_at":"2024-07-02T16:35:31.451Z","phase":"Phase 3","brief_title":"Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC","source_id_and_acronym":"NCT02273375 - ADJUVANT BR.31","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1415","initiation":"Initiation: 02/24/2015","start_date":" 02/24/2015","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-10-27"},{"id":"9d7802e8-9cf0-441c-8363-c53cf3be3c5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638167","created_at":"2021-01-18T17:51:52.507Z","updated_at":"2024-07-02T16:35:31.308Z","phase":"Phase 1","brief_title":"EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors","source_id_and_acronym":"NCT03638167","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2040","study_completion_date":" 03/01/2040","last_update_posted":"2023-10-27"},{"id":"c6b840a9-cde6-463f-aaed-d7a3262f6ba6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03735628","created_at":"2021-01-18T18:17:51.915Z","updated_at":"2025-02-25T17:10:37.499Z","phase":"Phase 1b/2","brief_title":"An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03735628","lead_sponsor":"Bayer","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR expression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/17/2018","start_date":" 10/17/2018","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2023-10-06"},{"id":"ce74a2bd-b0b5-477e-9e90-292a69fe06b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02947386","created_at":"2021-01-18T14:28:12.329Z","updated_at":"2024-07-02T16:35:34.575Z","phase":"Phase 1/2","brief_title":"Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02947386","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR expression • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 06/29/2017","start_date":" 06/29/2017","primary_txt":" Primary completion: 04/15/2021","primary_completion_date":" 04/15/2021","study_txt":" Completion: 09/08/2022","study_completion_date":" 09/08/2022","last_update_posted":"2023-10-05"},{"id":"12b49972-5a2a-42ac-8778-f1b01b3babed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06048913","created_at":"2023-09-21T14:10:56.196Z","updated_at":"2024-07-02T16:35:36.159Z","phase":"Phase 1","brief_title":"Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age","source_id_and_acronym":"NCT06048913","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 45","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-09-21"},{"id":"faa6b9ee-e5b7-4857-a716-679458f2b01b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01376505","created_at":"2021-01-18T05:38:31.071Z","updated_at":"2025-02-25T13:59:55.799Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Metastatic Solid Tumors","source_id_and_acronym":"NCT01376505","lead_sponsor":"Robert Wesolowski","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/21/2011","start_date":" 06/21/2011","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 11/28/2022","study_completion_date":" 11/28/2022","last_update_posted":"2023-09-15"},{"id":"328e86c2-f909-458a-bfed-3477f5be5a6e","acronym":"NOTABLE-307","url":"https://clinicaltrials.gov/study/NCT05978050","created_at":"2023-08-07T14:08:43.635Z","updated_at":"2024-07-02T16:35:40.808Z","phase":"Phase 3","brief_title":"Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","source_id_and_acronym":"NCT05978050 - NOTABLE-307","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-08-07"},{"id":"0b05481d-c3c1-4ad2-939c-6638e0bf26e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01068587","created_at":"2021-01-18T04:12:43.648Z","updated_at":"2025-02-25T13:15:36.669Z","phase":"Phase 1/2","brief_title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","source_id_and_acronym":"NCT01068587","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/21/2010","start_date":" 01/21/2010","primary_txt":" Primary completion: 03/21/2014","primary_completion_date":" 03/21/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"d9fd809b-eb43-4044-9ecf-63c36ff9e599","acronym":"","url":"https://clinicaltrials.gov/study/NCT04695847","created_at":"2021-01-19T20:49:32.993Z","updated_at":"2025-02-25T16:10:59.679Z","phase":"Phase 1","brief_title":"M1231 in Participants With Solid Tumors","source_id_and_acronym":"NCT04695847","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MSI • MUC1","pipe":" | ","alterations":" MSI-H/dMMR • EGFR expression","tags":["EGFR • MSI • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M1231"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 06/23/2023","study_completion_date":" 06/23/2023","last_update_posted":"2023-07-07"}]